ELAN
Elanco Animal Health, Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.49
−0.25%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$23.71
From 52W high−12.48%
Volume2.90M
Market cap$11.74B
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataOct 19, 2026
Open
$23.71
From 52W high
−12.48%
Volume
2.90M
Market cap
$11.74B
ValuationView details →
P/E (Fwd)
19.1x
EV/EBITDA
19.5x
P/E (TTM)
—
RSI (14)
58.9
MomentumView details →
1D Return
−0.25%
YTD Return
+4.24%
SummaryUpdated Jun 1, 2026
Elanco Animal Health Incorporated (NYSE:ELAN) is a leading global animal health company that develops, manufactures, and markets products for both companion animals (pets) and farm animals. Founded in 1954 as a division of Eli Lilly and Company, Elanco operated as part of the pharmaceutical giant for over six decades before being spun off as an independent public company in September 2018. The company is headquartered in Greenfield, Indiana, and has established itself as one of the largest animal health companies worldwide, serving veterinarians, pet owners, and livestock producers across more than 90 countries.
Similar companies
Latest newsMore news →
Purdue University and Elanco Animal Health Inc broke ground on a planned 150,000-square-foot One Health Research Institute in Indianapolis.4d agoBimeda launched MoxiSolv Pour-On (moxidectin), an FDA-approved topical parasiticide for beef and dairy cattle, as a bioequivalent alternative to Elanco's Cydectin Pour-On.27d ago